Though CHK1 deficiency has been reported to induce early embryonic lethality in vivo,219 the knockdown of which is preferentially more deleterious in tumor cells than in normal cells, suggesting the potential of Chk1 as a therapeutic target in cancer treatments. The gene discussed is CHEK1; the disease is cancer.